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Background: The accumulation of amyloid beta (Aβ) oligomers or fibrils is thought to be one of the main causes
of synaptic and neuron loss, believed to underlie cognitive dysfunction in Alzheimer’s disease (AD). Neuron loss has
rarely been documented in amyloid precursor protein (APP) transgenic mouse models. We investigated whether
two APP mouse models characterized by different folding states of amyloid showed different neuronal densities
using an accurate method of cell counting.
Findings: We examined total cell and neuronal populations in Swedish/Indiana APP mutant mice (TgCRND8) with
severe Aβ pathology that includes fibrils, plaques, and oligomers, and Dutch APP mutant mice with only Aβ
oligomer pathology. Using the isotropic fractionator, we found no differences from control mice in regional total
cell populations in either TgCRND8 or Dutch mice. However, there were 31.8% fewer hippocampal neurons in
TgCRND8 compared to controls, while no such changes were observed in Dutch mice.
Conclusions: We show that the isotropic fractionator is a convenient method for estimating neuronal content in
milligram quantities of brain tissue and represents a useful tool to assess cell loss efficiently in transgenic models
with different types of neuropathology. Our data support the hypothesis that TgCRND8 mice with a spectrum of
Aβ plaque, fibril, and oligomer pathology exhibit neuronal loss whereas Dutch mice with only oligomers, showed
no evidence for neuronal loss. This suggests that the combination of plaques, fibrils, and oligomers causes more
damage to mouse hippocampal neurons than Aβ oligomers alone.
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Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder characterized by the presence of extra-
cellular amyloid beta (Aβ) plaques, neurofibrillary
tangles, and severe loss of synapses and neurons [1].
One of the limitations of AD mouse models has been
the absence of cell loss in many of them [2–4], although
systematic head-to-head comparison of neuronal loss in
mouse models has been hindered by the fact that high-
quality morphometry is not routinely available or* Correspondence: dara.dickstein@mssm.edu
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distribution, and reproduction in any mediumachieved. Furthermore, there are a number of non-
stereologic approaches, prone to observer biases, which
are often employed but fail to produce comparable
results, within a laboratory as well as across studies. As
a result, reliable quantification of neuronal loss has not
been routinely included in the characterization of mouse
models. Absence of data on neuronal loss reduces the
usefulness in specifying how particular transgenes and
interventions impact neuronal integrity. Here, we exam-
ined changes in total cell (i.e., neurons and glia) and
total neuronal numbers and densities in two mouse
models of AD harboring different APP mutations and
exhibiting different panoplies of Aβ biophysical pheno-
types: the TgCRND8 mouse and the Dutch APP mouse.
TgCRND8 mice express the Swedish (K670M/N671L)tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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increases in total production of Aβ and in the Aβ42/Aβ40
ratio, leading to accumulation of intraneuronal Aβ, Aβ
amyloid plaques, soluble oligomeric Aβ (oAβ), and insol-
uble fibrillar Aβ (fAβ) [5]. The Dutch mouse expresses
the E693Q mutation that favors the production of oAβ
over fAβ and accumulates intraneuronal Aβ and oAβ [3]
(Additional file 1: Table S1; Figure 1).
We employed the isotropic fractionator method [6],
and quantified cell and neuronal populations in these
two different APP mouse lines that we predicted would
demonstrate different levels of neuronal integrity. When
comparing our total cell numbers to published estimates
from wildtype mouse brains, we found that they were
comparable to those reported for whole brain using the
isotropic fractionator [7], and for specific brain regions
such as the cerebellum, as estimated by isotropic fractio-
nator and flow cytometry [8], and the hippocampus as
assessed by traditional stereology [9–12] (Table 1).
When assessing total cell and neuron populations, we
found no differences in total and regional brain weights
between transgenic mice and their respective littermates.
We also did not find any differences in total cell counts
or densities between TgCRND8 mutant APP mice and
controls (Figure 2A-F). However, we observed signifi-
cantly fewer (31.8%) hippocampal neurons between
TgCRND8 mutant APP mice and their non-transgenic
littermates (t(12) = 2.391, p = 0.033; Figure 2H). No sig-
nificant differences were observed in total neuronal
counts or densities in neocortex or cerebellum
(Figure 2G, I-L). When we studied Dutch mutant APP
mice, we found no significant differences from controls
in total cell count, neuronal cell count, cell density, or
neuronal density (Figure 2). We did not observe neur-
onal density changes in the neocortex, perhaps because
of region- or even layer-specific vulnerability of selectFigure 1 APP/Aβ pathology in the hippocampus of TgCRND8 mutant
were visualized using the 6E10 antibody. Extracellular amyloid plaques (aste
old), while (C) Dutch mutant APP (17 months old) exhibit intracellular APP/
when 6E10 is used to immunostain brain of a wild type mouse (A). Inset p
plaques in TgCRND8 mutant APP mice and intracellular APP/Aβ-LIR in Dutc
represent 100 μm.neuronal populations. We did not assess neuron num-
bers in specific neocortical regions and, as such, any
locally restricted loss may have been undetected. We also
analyzed mice at only one time point and it is possible that
neocortical neuronal loss may appear at later stages.
Aberrant accumulation of brain Aβ over decades has
been proposed to result in synaptic and neuronal loss
associated with the progression of AD (for review see
[13]). Evidence indicates that accumulation of soluble
oAβ relates to cognitive impairment in AD patients [14]
and AD mouse models [2,3,15]. However, the possibility
that the severity of neurotoxicity and neuronal loss may
be related to levels of Aβ solubility or confirmation (oAβ
or fAβ) remains unclear. Using high-resolution 3D
reconstructions, intraneuronal accumulation of fAβ has
been observed by some investigators who proposed that
this fAβ leads to the disruption and degeneration of
spines and neurites, and ultimately to neuronal death
[16], even though other investigators have reported that
oAβ alone is sufficient for behavioral dysfunction [15].
Importantly, other studies have demonstrated reduced
neuron densities in various lines of APP mice following
onset of plaque pathology. These observations were pri-
marily derived from the hippocampus and are similar in
magnitude to the loss we report in TgCRND8 mice,
albeit using different counting methods (Table 1). Using
a stereologic approach, Calhoun et al. (1998) found
a ~25% loss of CA1 neurons in TgAPP23 mice, while
Schmitz et al. (2004) found a ~30% loss of neurons in
the CA1-3 regions in an APP/PS1 double mutant mouse,
and Breyhan et al. (2009) found a 33% loss of CA1
pyramidal neurons in APP/PS1 knock-in mice. Our
results indicate that, in wildtype mice, estimates derived
from the isotropic fractionator are generally comparable
to stereologic estimates. Most importantly, we observed
an apparent neuronal loss in TgCRND8 mice that formAPP and Dutch mutant APP transgenic mice. Aβ and APP species
risk) are evident in (B) TgCRND8 APP transgenic mice (3.5 months
Aβ-like immunoreactivity (APP/Aβ-LIR; arrow). No APP/Aβ-LIR is seen
anels represent higher magnification of 6E10 immunoreactivity of
h mutant APP mice. Scale bars represent 500 μm. Scale bars in insets
Table 1 Summary of cell and neuron counts from different studies according to brain region and counting method
Method Genetic background Brain region Cell or neuron
number





Whole brain 100.10 ± 7.90 x 106 6 months; K670M/N671L/V717F APP Present study
Dutch (C57BL/6J)
Isotropic Fractionator Swiss Webster Whole brain 108.90 ± 16.25 x 106 2-5 months [7]
Isotropic Fractionator TgCRND8 (C3H/He-C57BL/6) Cerebellum 43.92 ± 2.78 x 106 6 months; K670M/N671L/V717F APP Present study
Dutch (C57BL/6J)
Isotropic Fractionator Swiss Webster Cerebellum 49.17 ± 5.32 x 106 2-5 months [7]
Isotropic Fractionator/
Flow Cytometry
C57Bl/6J Cerebellum 44.03 ± 0.42 x 106 60-100 days [8]
Isotropic Fractionator TgCRND8 (C3H/He-C57BL/6) Hippocampus 31.8% decrease
in neurons
6 months; K670M/N671L/V717F APP Present Study
Isotropic Fractionator Dutch (C57BL/6J) Hippocampus No decrease in
neurons
18 month Dutch E693Q APP mice Present study






(CBA - 12.5% × C57Bl6 - 87.5%)
CA1-CA3 ~30% decrease
in neurons








10 month APPSLPS1KI (APP K670N/M671L,
and V717I; PS1 M233T/L235P knock-in)
[11]
Stereology C57BL/6J CA1 33% decrease
in neurons
6 month APP/PS1KI [12]
(APP K670N/M671L, and V717I;
PS1 M233T/L235P knock-in)
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Dutch mice that produce only oAβ. It is evident that
both oAβ and fAβ are toxic and implicated in the
neurodegeneration process. However, various Aβ spe-
cies may impair neuronal function via different




Eight 6-month-old TgCRND8 APPK670N/M671L/V717F
mice and seven wildtype littermates, as well as nine
18-month-old Dutch APPE639Q mice and eight of their
littermates were used in this study. These ages were
chosen as previous studies demonstrated clear behav-
ioral impairments and amyloid deposition in the
TgCRND8 mice and intracellular accumulation in the
Dutch mice at these time points [3,5]. All mice used in
the current study were group-housed, given ad libitum
access to food and water, and housed under a 12-hour
light/dark cycle. All animal procedures were conducted
in accordance with the National Institute of Health
Guidelines for the Care and Use of Experimental
Animals and were approved by the Institutional Animal
Care and Use Committee of the Icahn School of Medi-
cine at Mount Sinai.Animals were perfused as previously described [17].
Brains were removed from the skull and postfixed in 4%
PFA at 4°C. Brains were weighed, cut into half, and
further dissected into three regions, cerebellum, hippo-
campus, and neocortex and weighed. Results were multi-
plied by 2 to obtain estimates of cell numbers for the
entire brain. In addition, brains were immunostained
with the anti-amyloid monoclonal antibody 6E10
(Covance) as described in [15].
Isotropic fractionator
The isotropic fractionator is a fast and reliable technique
for determining total cell and neuronal counts and cell
densities in the brain. The procedure involves processing
of highly anisotropic brain structures into homogeneous
isotropic suspensions of cell nuclei that can be easily
quantified [6]. Because the estimates of cell counts are
obtained separately from the determination of brain vol-
ume, the two measurements can be used in comparative
studies of brain-volume variation (i.e., comparing across
species or between different mouse lines [6]). Briefly,
postfixed samples were mechanically dissociated and
homogenized in a solution of 40 mM sodium citrate and
1% Triton X-100 as previously described [6]. The homo-
genates were collected and the homogenizer washed at
least twice to collect any residual cells. To visualize nuclei
Figure 2 TgCRND8 mutant APP transgenic mice exhibit significantly lower neuronal numbers and densities as compared to Dutch
mutant APP transgenic mice. There was a significant difference observed in neuronal numbers in the hippocampus between TgCRND8 mutant
APP mice and their control littermates (H). Left column represents TgCRND8 mutant APP mice (black) and their littermate controls (grey) and the
right column represents the Dutch mutant APP mice (black) and their littermate controls (grey). Note that the scale of the y-axis changes among
the graphs. Values represent mean ± SEM. *p < 0.05.
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phenylindole (Sigma) was added to the cell suspension
(volumes according to brain region; 10 ml for cerebellum
and neocortex, 3 ml for hippocampus. The volume for
each brain region was optimized so that at least 500 nuclei
could be counted) To determine total neuron counts, 1 ml
of each cell suspension was removed, washed with PBS,
and centrifuged for 10 minutes at 4000 x g. Cells were
then incubated in anti-NeuN antibody (1:200; Millipore)for 2 hours followed by incubation in a secondary anti-
mouse IgG-Alexa-Fluor 594 for 1.5 hours (1:200;
Millipore). Cells were then counted with a hemocytometer
using a 20X/0.45 N.A., Plan-Apochromat objective on a
Zeiss Axiophot microscope equipped with a motorized
stage. All four quadrants in both the upper and lower
grids of the hemocytometer were counted and averaged.
Total cell numbers and neuronal numbers were calculated
by multiplying the number of cells/ml by final volume.
Brautigam et al. Molecular Neurodegeneration 2012, 7:58 Page 5 of 5
http://www.molecularneurodegeneration.com/content/7/1/58Densities were calculated by dividing the number of cells/
ml by the mass of brain region.
Statistics
All statistical analyses were performed using SPSS v19.0.
Independent samples t-tests were used for comparison
of TgCRND8 mutant APP or Dutch mutant APP mice
to their respective littermates. Levene's test for homo-
geneity of variance was used for inclusion in parametric
tests (p > 0.05). Significance for t-tests are reported with
a p value < 0.05 using two-tailed tests with an α level of
0.05. Values represent mean ± SEM.
Additional file
Additional file 1: Table S1. Comparison between the DutchAPPE693Q
mouse model and the TgCRND8APPK670N/M671L/V7F mouse model [2–5].
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